Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
Mar 11 2019
•
By
Bridget Silverman
Even if a development-stage product loses Breakthrough designation from the US FDA, it's regulatory progress isn't necessarily going in reverse.
More from Review Pathways
More from Pathways & Standards